Genmab A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jan van de Winkel
- Full Time Employees
- 2,638
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Kalvebod Brygge 43 Copenhagen Denmark 1560
- IPO Date
- Jun 1, 2009
- CIK
- 0001434265
- Website
- genmab.com
- Similar Companies
- Business
- Genmab A/S develops differentiated antibody therapeutics targeting cancer and other serious diseases using proprietary platforms including DuoBody, HexaBody, UniBody and HuMab-Mouse technologies; core products encompass approved medicines such as EPKINLY (epcoritamab, a CD3xCD20 bispecific T-cell engager for relapsed/refractory diffuse large B-cell lymphoma marketed with AbbVie), TIVDAK (tisotumab vedotin, a tissue factor-directed antibody-drug conjugate for recurrent/metastatic cervical cancer marketed with Seagen), royalties from partner-marketed DARZALEX (daratumumab for multiple myeloma and AL amyloidosis by Janssen), Kesimpta (ofatumumab for relapsing remitting multiple sclerosis by Novartis), RYBREVANT (amivantamab for non-small cell lung cancer by Janssen), TECVAYLI and TALVEY (teclistamab and talquetamab bispecifics for relapsed/refractory multiple myeloma by Janssen) and TEPEZZA (teprotumumab for thyroid eye disease by Horizon); the company advances a broad pipeline of proprietary and partnered bispecific antibodies, antibody-drug conjugates and immune checkpoint modulators in oncology and autoimmune indications. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates globally through subsidiaries in the Netherlands, United States, Japan, Germany and China, serving pharmaceutical partners and patients across North America, Europe and Asia Pacific. Recent developments include the 2024 acquisition of ProfoundBio for $1.8 billion to bolster its antibody-drug conjugate capabilities (with subsequent discontinuation of certain assets), the September 2025 announcement of an $8 billion acquisition of Merus to integrate petosemtamab (a late-stage bispecific for head and neck cancer) and accelerate transition to a wholly owned model, successful independent launches and international expansions of EPKINLY and TIVDAK in Europe and Japan, and positive Phase III data for epcoritamab expansions plus Rina-S programs driving projected double-digit revenue growth to $3.5-3.7 billion in 2025.
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab Announces Financial Results for the First Quarter of 2026
Genmab A/S Share Capital Reduction
Major Shareholder Announcement
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Genmab: Multiple Binaries Could Alter The Thesis
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Major Shareholder Announcement
Major Shareholder Announcement
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Passing of Genmab A/S' Annual General Meeting
Completion of Share Buy-back Program
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB